The European Medicines Agency thinks that the advantages of the Astrazeneca vaccine against Covid-19 outweigh the disadvantages by far, states the agency at a press conference Wednesday afternoon.
For this reason, the agency maintains is recommendation that the vaccine should be put to use in EU vaccination programs in spite of the fact that safety experts within the agency see a possible connection between the vaccine and the incidents involving blood clots that have been reported on in recent weeks involving people who have received the vacine.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.